Lynn Sullivan

Chief Business Officer Rose Pharma

Lynn is a pioneer in commercializing GLP-1 therapies, having led the launches of Ozempic®, Saxenda®, Wegovy®and oral Ozempic® called Rybelsus®. With 30+ years of experience bringing novel drug mechanisms and new therapeutic categories to market - including Prilosec®, Actos®, and Humira® - She has a proven track record of shaping strategy and building blockbuster brands in emerging markets. Today, she leads a biotech company with a Phase 2 product being advanced with two indications: Reduction of IBS Pain and Weight Management.

Pharma Launch Excellence Summit Conference Day 1: Wednesday September 30

2:30 PM Roundtable Discussion Groups

Small groups. No slides. No spectators.

Each table is built around a problem teams are actively trying to solve:

• Fixing weak uptake in the first 90 days post-launch

• Getting Medical, Access and Commercial aligned before approval

• What to cut when launch budgets tighten

• Where AI is actually saving time in launch execution

• Dealing with payer pushback on high-cost therapies

You'll leave with:

• How others are approaching it

• What's working vs failing

• Practical ideas you can take straight back

Rountables Include:

AI in Launch: Turning Experimentation into Measurable Impact
Access, Pricing and Affordability as Launch Strategy]
Medical Affairs, Evidence and Scientific Engagement Before Launch
Turning Launch Strategy into Launch Performance
Field Execution, Commercial Ops and Launch Infrastructure

Pharma Launch Excellence Summit Conference Day 2: Thursday October 1

10:30 AM Building the Launch Culture Behind a Blockbuster: Lessons from GLP-1 Market Creation

Launching a product in an established category is one challenge. Building belief in an emerging therapeutic area is another. When GLP-1s were still early in obesity and diabetes, success depended not only on strategy, data and messaging, but on creating the internal culture, field confidence and market education needed to turn uncertainty into momentum.

Drawing on experience leading diabetes and obesity commercial teams across the US and global markets, this session will explore how to build the people, tools and operating rhythm behind a high-growth launch, from motivating field teams and aligning affiliates to creating consistent global execution across diverse local markets.

• Building internal belief and field confidence around emerging therapeutic areas

• Aligning global strategy with local market fit across multiple countries

• Using launch platforms, training and KPIs to create execution visibility

• Creating a pioneering culture that turns launch teams into business builders

Check out the incredible speaker line-up to see who will be joining Lynn.

Download The Latest Agenda

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: 44 (0) 207 368 9300
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk